R

Rallybio Corp
NASDAQ:RLYB

Watchlist Manager
Rallybio Corp
NASDAQ:RLYB
Watchlist
Price: 0.785 USD 0.93% Market Closed
Market Cap: 33.2m USD

Net Margin
Rallybio Corp

-2 095.9%
Current
-4 453%
Average
-6.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 095.9%
=
Net Income
-14.1m
/
Revenue
674k

Net Margin Across Competitors

No Stocks Found

Rallybio Corp
Glance View

Market Cap
32.9m USD
Industry
Biotechnology

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 35 full-time employees. The company went IPO on 2021-07-29. The firm is engaged in discovering, developing, manufacturing and delivering therapies that improve the lives of patients suffering from severe and rare diseases. The company offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. The company provides RLYB211, a polyclonal anti-HPA-1a antibody. Its RLYB211 is in Phase I/II clinical trial. The Company’s lead product candidate, RLYB212, is a monoclonal anti-HPA-1a antibody. The company is also focused on developing therapies that address diseases of complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and ophthalmic disorders. Its RLYB116 is a long-acting, subcutaneously administered inhibitor of complement factor 5 (C5) in development for the treatment of patients with PNH and gMG. The company also includes RLYB114, which is a pegylated C5 inhibitor.

RLYB Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 095.9%
=
Net Income
-14.1m
/
Revenue
674k
What is the Net Margin of Rallybio Corp?

Based on Rallybio Corp's most recent financial statements, the company has Net Margin of -2 095.9%.

Back to Top